Edition:
United Kingdom

Protagonist Therapeutics Inc (PTGX.OQ)

PTGX.OQ on NASDAQ Stock Exchange Global Market

18.99USD
15 Dec 2017
Change (% chg)

$0.76 (+4.17%)
Prev Close
$18.23
Open
$18.29
Day's High
$19.44
Day's Low
$18.29
Volume
184,135
Avg. Vol
37,916
52-wk High
$23.35
52-wk Low
$8.00

Select another date:

Thu, Dec 14 2017

BRIEF-Protagonist Therapeutics Appoints Sarah Noonberg To Board

* PROTAGONIST THERAPEUTICS APPOINTS SARAH NOONBERG TO THE BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-Protagonist Therapeutics Announces Final Phase 1 Study Results With Novel Hepcidin Mimetic, PTG-300

* PROTAGONIST THERAPEUTICS ANNOUNCES FINAL PHASE 1 STUDY RESULTS WITH NOVEL HEPCIDIN MIMETIC, PTG-300

BRIEF-Protagonist Therapeutics initiates phase 1 trial of oral peptide PTG-200

* Protagonist Therapeutics initiates phase 1 trial of oral peptide IL-23 receptor antagonist, PTG-200

BRIEF-Protagonist Therapeutics Q3 ‍net loss per share $0.29​

* Protagonist Therapeutics reports third quarter 2017 financial results and provides corporate update

BRIEF-Protagonist Therapeutics prices offering of 3.53 mln common shares at $17 per share

* Says public offering of 3.53 million common shares priced at $17.00 per share Source text for Eikon: Further company coverage:

BRIEF-Protagonist Therapeutics announces proposed public offering of common stock

* Protagonist Therapeutics announces proposed public offering of common stock

BRIEF-Protagonist Therapeutics Inc files for mixed shelf of up to $200 million - SEC filing ‍​

* Protagonist Therapeutics Inc files for mixed shelf of up to $200 million - SEC filing ‍​ Source text: (http://bit.ly/2xDBQBh) Further company coverage:

BRIEF-Protagonist Therapeutics announces closing of Janssen license

* Protagonist Therapeutics announces closing of Janssen license and collaboration agreement for PTG-200 and receipt of $50 million payment

BRIEF-Protagonist Therapeutics reports Q2 loss per share of $0.89

* Protagonist therapeutics reports second quarter 2017 financial results and business highlights

Select another date: